

2nd European Iron Academy

26–27 March 2015, Paris, France

Learning Objectives

Plenary sessions

Plenary sessions will be attended by all participants at the 2nd European Iron Academy. For further details about the event programme, please refer to the detailed agenda.

Day 1

Global burden of anaemia and ID(A)

Upon completion of this session, participants should be able to:

1. Describe the global prevalence of, and risk factors for ID/IDA, in terms of nutritional causes, underlying medical conditions and socio-economic aspects
2. Describe main symptoms associated with ID and its main diagnostic biomarkers
3. Appreciate the clinical, social and economic consequences of ID/IDA

Physical symptoms and diagnosis

Upon completion of this session, participants should be able to:

1. Describe the main clinical features of absolute and functional ID in different disease settings, including oncology, gastroenterology, cardiology and women's health
2. Demonstrate a knowledge of the key diagnostic techniques for the detection of ID/IDA
3. Demonstrate awareness about the underdiagnosis and undertreatment of ID/IDA, and the importance of addressing this problem

Introduction to iron metabolism and clinical picture of ID/IDA

Upon completion of this session, participants should be able to:

1. Describe the physiological role of iron in the human body
2. Understand the mechanisms of iron homeostasis and metabolism
3. Describe the difference between absolute and functional ID, with a focus on the role of inflammation
4. Understand the pathophysiology of ID/IDA and latest research in this area

New data in iron trials – what does this mean for patients?

Upon completion of this session, participants should be able to:

1. Demonstrate an awareness of the latest clinical developments in treatment of ID
2. Describe key data from recent clinical trials of treatment with parenteral iron formulations in pregnancy, chronic heart failure (CHF) and chronic kidney disease (CKD)

Day 2

Health economics and ID

Upon completion of this session, participants should be able to:

1. Understand the health-economic impact of ID in different patient populations
2. Demonstrate awareness about the available cost-effectiveness data for the treatment of ID

Monitoring patients and maintenance therapy

Upon completion of this session, participants should be able to:

1. Describe the rationale for iron maintenance therapy in patients with ID
2. Demonstrate an understanding of the key principles of monitoring iron parameters in patients receiving maintenance intravenous (IV) therapy
3. Discuss the available clinical trial data for IV iron maintenance therapy in different patient populations

IV iron preparations and safety

Upon completion of this session, participants should be able to:

1. Summarise the potential safety issues with currently available IV iron therapies
2. Discuss the key safety data from clinical trials on the use of IV iron
3. Understand how best to monitor adverse events in patients undergoing treatment with IV iron

Parallell sessions

Over the two days of the meeting, participants will attend four different sessions of their choosing from the following options below. For further details about the event programme, please refer to the agenda.

Cardiology

Upon completion of this session, participants should be able to:

1. Understand the clinical significance of ID in patients with cardiovascular disease, particularly in CHF
2. Demonstrate an awareness about the advantages and limitations of different diagnostic approaches for ID in cardiology
3. Demonstrate an awareness about the benefit of iron therapy for improving outcomes of CHF patients with ID/IDA

Gastroenterology

Upon completion of this session, participants should be able to:

1. List the three major causes of ID in gastrointestinal (GI) disorders (bleeding, inflammation and malabsorption)
2. Demonstrate an awareness of the impact of ID/IDA on QoL and outcomes in patients with GI disorders including inflammatory bowel disease (IBD), GI bleeding, coeliac disease and obesity, and those undergoing bariatric surgery
3. Outline the key principles of treatment for ID/IDA in GI disorders, with an awareness of the benefits and disadvantages of the treatment options available

ID in Surgery

1. Understand the importance of patient blood management (PBM) and pre-operative management of ID/IDA
2. Describe the challenges of ID/IDA management in different types of surgery, including bariatric, cardiac and gynaecological surgery

Nephrology

Upon completion of this session, participants should be able to:

1. Understand the burden and pathogenesis of ID/IDA in CKD, as well as its clinical outcomes and impact on patient quality of life (QoL)
2. Describe the specific challenges of ID diagnosis in CKD and identify appropriate markers for identifying ID in CKD
3. Outline diagnostic and treatment guidelines for ID/IDA in CKD, with an awareness of the benefits/disadvantages of the different treatment options

Pharmacoeconomics of iron therapy

Upon completion of this session, participants should be able to:

1. Demonstrate an awareness of the societal cost of ID
2. Understand the costs and benefits – and disadvantages – associated with the available ID treatment options
3. Engage in a discussion with hospital pharmacists about the value of different treatment options for ID/IDA, with reference to specific groups of patients

Cardiology/renal

Upon completion of this session, participants should be able to:

1. Understand the link between heart failure, kidney failure and anaemia, and the vicious cycle of deterioration that they cause in patients with cardio-renal syndrome
2. Demonstrate an awareness of the clinical data supporting the use of iron-replacement therapy in CHF and CKD
3. Describe the optimal diagnostic and treatment methods for patients with CHF and CKD

Haematology and oncology

Upon completion of this session, participants should be able to:

1. Explain the effects of ID/IDA in cancer patients in terms of reduced QoL, morbidity and mortality
2. Demonstrate an awareness of the types of cancer in which ID/IDA pose a particular problem
3. Describe management options for ID in cancer patients, including breast cancer and GI tumours

ID in the elderly

Upon completion of this session, participants should be able to:

1. Understand the impact of ID/IDA on elderly people
2. Describe the clinical features of ID/IDA in the elderly, including its effect on physical function, risk of falls, cognitive impairment and mortality
3. Describe the challenges associated with diagnosing ID/IDA in elderly patients and the importance of diagnosing ID before IDA develops

Optimal dosing and monitoring of IV iron therapy

Upon completion of this session, participants should be able to:

4. Describe the key safety data on the use of IV iron from clinical trials
5. Demonstrate an awareness of the key principles of monitoring iron parameters in patients receiving IV iron therapy

Postpartum and heavy menstrual bleeding

Upon completion of this session, participants should be able to:

1. Understand the pathogenesis and burden of ID/IDA in women's health: pregnancy, post-partum and heavy menstrual bleeding patients
2. Describe the diagnostic signs and symptoms of ID/IDA in a variety of patient types, including pregnancy, post-partum and heavy menstrual bleeding patients
3. Outline the guidelines of ID management in women's health